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A few precepts
• To be of value, a combination must be more effective, show reduced toxicity, or cost 
significantly less than each component.
• Statistical significance should support biological significance, i.e. a 10% reduction of 
morbidity/mortality, even if significant statistically, may not be worth routinely rais-
ing the cost of treatment form $100/day to thousands of dollars/day. Alternatively, a 
marked reduction of mortality/morbidity (e.g. 50%) may be well worth additive costs.
• A superior combination might not take hundreds of patients to demonstrate it. On the other 
hand, too many case series consist of very small numbers insufficiently powered to be conclu-
sive, and (excepting cryptococcosis) almost all are historical series. Case series may prompt 
randomized controlled trials, but are rarely sufficient in themselves to change medical prac-
tice. Randomized controlled trials should be designed to answer the most critical questions, 
and should have criteria for entry and for outcome evaluation clearly defined in the protocol.
© 2012 ACIN. Published by Elsevier España, S.L. All rights reserved.
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Introduction
For systemic mycoses, the potential of combinations began 
with the appearance of a second major antifungal drug 
in the 1970’s. Flucytosine (5FC) has a limited spectrum 
against Candida species, Cryptococcus neoformans, and 
a few other fungal pathogens. Because of toxicity and 
limited clinical responses to amphotericin B, flucytosine 
was evaluated in combination with amphotericin B in the 
treatment of cryptococcal meningitis1. Reduced toxicity 
and increased efficacy of the combination in this relatively 
small benchmark study led to the adoption of combined 
amphotericin B/flucytosine as the standard therapy for 
cryptococcal meningitis. Just as important, it led to the 
formation of the Mycoses Study Group (MSG). This National 
Institutes of Health supported collaborative was formed 
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My assessment is also yes – but only for cryptococcal meningi-
tis. Multiple studies of cryptococcal meningitis have given us 
a clear roadmap of what we should accomplish to show ben-
efit of combinations against other mycoses. However, despite 
a lot of in vitro and mouse studies, and a very few adequate 
human studies, there remains uncertainty of the significant 
benefit of combined antifungal therapy for candidiasis and 
molds. If one adds the costs and potential toxicities of sus-
tained combined therapy, there may more even more nega-
tives than simple inefficacy. Multicenter studies are costly, 
and in general evaluate only two  regimens. In the case of 
combined antifungal therapy, we will see drug A and drug 
A plus drug B, but rarely drug B alone. So already we are at 
some disadvantage. The waters are muddied further in that, 
when we do salvage studies, many patients have previously 
received courses of AMB, an agent with very slow terminal 
clearance. We have generally ignored this potential contribu-
tion of at least low levels of a “third” drug. Other salvage 
studies include clinical failures and toxicity failures. As one 
example of the differences, caspofungin (CSP) salvage shows 
much more benefit in toxicity failures than clinical failures. 
The following comments present a view that we have not yet 
reached a point of adopting combined antifungal as standard 
for either Candida or mold infections. I will present some 
reasoning as to why this may be inevitable, given the nature 
of our mold IFI, and I will suggest another line of investiga-
tion which is at our doorstep, and may prove more beneficial 
than our selection of antifungal drug combinations. This is 
not a unique view, and has recently been published in an 
excellent review by Dr Luis Ostrosky-Zeichner5. Not so much 
has changed between 2008 and 2012.
The role of preclinical data  
(which I am not going to detail here)
In vitro
There have been many publications presenting in vitro data 
on combination versus single drug effect on fungal patho-
gens. Many of these present the fractional inhibitory con-
centration of individual and combination regimens. When 
the activity of the combination exceeds the activity of single 
drugs this is defined as an additive or a synergistic effect. By 
contrast, when the effect of combinations is less than single 
drugs this is defined as an antagonistic effect. The advan-
tage of this system is the ability to change the conditions of 
the test in many ways, including: drug concentrations, the 
time they are added to the cultures, incubation conditions, 
measurement of overall inhibitory effect (inhibiting growth, 
killing organisms, or changing the morphology of organisms 
[echinocandins and molds]), or by interference with meta-
bolic processes of pathogens. The same advantages, of mul-
tiple conditions for tests, may also be a disadvantage when 
we try to extrapolate from the test tube to the patient. 
Through these in vitro tests we reach a consensus, usually 
rather empirically, on what may be clinically significant… but 
without a great deal of certainty in many cases.
I find in vitro data on antifungal agents, alone, very 
unconvincing. As examples I would use 1) AMB, which kills 
Aspergillus, Mucor, and a host of other organisms very 
rapidly in vitro, but is very often associated with clinical 
at the time of the dramatic expansion of HIV/AIDS. The 
rise of invasive fungal infections (IFI) prompted aggres-
sive development of the azole class of antifungal agents 
and more recently, the echinocandins. The MSG set about 
the evaluation of novel antifungal regimens for prevention 
and treatment of cryptococcosis, the endemic mycoses of 
North America, systemic candidiasis, and most recently, 
invasive mold infection. New treatments for cryptococco-
sis and histoplasmosis have substantially reduced the mor-
tality of these two diseases. In the case of histoplasmosis, 
this was aided by the development of Histoplasma antigen 
detection, which decreased the time for diagnosis from 
weeks to days. As treatment for HIV improved, the inci-
dence and mortality of cryptococcosis and endemic fungal 
infections also decreased.
As the acute IFI of AIDS came under control, largely 
through controlling HIV itself, improvements in chemo-
therapy of malignancies (particularly hematological), 
antibodies targeted against a number of inflammatory 
mediators (such as tumor necrosis factor) and a rapid 
increase in solid organ transplantation opened a new era 
in IFI. Candidemia increased in high risk groups, but was 
reduced by use of fluconazole prophylaxis, though Candida 
glabrata has emerged as an increasing problem in hospi-
talized patients in the US and Europe. Most recently, the 
center stage has been taken over by mold infections. Of 
these, invasive aspergillosis (IA) accounts for about 70-80% 
of mold infections. The zygomycetes (Mucorales) account 
for about 10-12%, and the remainder are divided among 
Scedosporium and a series of less common molds. Until 
the development of voriconazole (VOR), the mortality of 
IA has remained a distressingly high 65-85%, depending in 
part on the underlying disease, the level of immune sup-
pression, and virulence of the pathogen. VOR, licensed 
as a first line treatment, (and unlicensed as prophylaxis), 
has led to successful outcomes in IA of 52% versus 32% for 
amphotericin B (AMB), a superior result2. However, VOR 
has no effects on Mucorales. A newer antifungal azole, 
posaconazole, is effective in prophylaxis of IA in patients 
with hematological malignancies and in rescue of patients 
with mucormycosis, histoplasmosis, aspergillosis, coccid-
ioidomycosis, cryptococcosis, and other mycoses3. How-
ever, both VOR and posaconazole have pharmacokinetic 
problems, and VOR has significant toxicities. Add to this 
the recent appearance of three very potent and very simi-
lar echinocandins, with great potency in candidiasis, no 
efficacy in cryptococcosis, and some efficacy in IA4. There 
is now a much broader range of drugs and drug classes 
available than a few decades ago.
At present, patients are still suffering and dying with IFI, 
the most common ones now being the molds. The obvious 
question becomes, if one of these drugs is effective against 
fungus “X,” will two drugs be more effective? Can we reduce 
the morbidity and mortality of IFI with combination antifun-
gal therapy? Can we do it as primary therapy and/or salvage 
therapy? Recent medical literature has shown what one drug 
can do in a number of well done studies on each of these new 
antifungals. We want to do better by our patients. We need 
to do better. Can we get there with combined antifungals?
Dr Kibbler and I have essentially the same pool of evi-
dence on which to base our assessment. He is led to the con-
clusion that there is value in combined antifungal therapy. 
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failure and 2) echinocandins, which were initially, on the 
basis of MIC, considered less effective against Candida 
parapsilosis6. Recently, and very quietly, the recommen-
dations against echinocandins for C. parapsilosis group 
were downgraded. The reason is that echinocandins were 
clinically effective per response and survival against C. 
parapsilosis7. So what role do in vitro data play in devel-
opment of new regimens? Essentially, they give us a series 
of “effective” concentrations to take to the next level.
Animal studies: The next level
Preclinical animal studies add several critical criteria to the 
evaluation of novel antifungal regimens. These include:
1) Drug kinetics: This includes whether the drug is 
absorbed orally or must/can be given intravenously (for 
the latter it must be solubilized in vehicles, which are 
themselves soluble in an aqueous environment). Amphot-
ericin B and echinocandins are used clinically only intra-
venously, while azoles, in general, can be given orally 
or intravenously (excepting posaconazole at this time). 
Animal studies help determine whether the drug achieves 
serum levels effective against fungus “X” as determined 
by previous in vitro studies. They also answer whether the 
drug penetrates to and remains in a target site of infec-
tion long enough to have efficacy (pharmacodynamics). 
Finally, they give us the rate of clearance and how a drug 
is metabolized? However, laboratory animal drug clear-
ance is not analogous to human clearance, and in mice is 
often much more rapid.
2) Drug efficacy: animal studies help us determine the dos-
ing route, amount, and frequency conditions for maximum 
efficacy (measured as survival and/or morbidity and/or 
reduction of fungal burden) and minimal or “acceptable” 
toxicity. Acceptable is determined, in part, by the nature 
of the mycosis being treated. Kinetics of drug disposition 
are very different in animal models than in humans (for 
example, in mice oral AMB is absorbed and effective, but 
not in humans). For chronic diseases one must perform 
chronic studies of drug treatment to check long term 
toxicity. One must also use at least two different animal 
models to determine an effective regimen. And finally, if 
one is to treat meningitis, which may restrict drug access 
across the blood brain barrier, one must use appropriate 
animal models… of meningitis.
3) Animal models are a critical antecedent to clinical stud-
ies. In 15 years of studies with new antifungals provided 
through the National Institutes of Health, we have found 
many effective in vitro, but much less than 5% effective 
and tolerated in animals. This is for single drugs. When 
one considers combinations, the process may become even 
more complex. To evaluate a single regimen one must use 
at least 8-10 animals in each treatment group. That is, for 
drug A, drug B, and drug A+B, 30 animals are used… just to 
look at one dose for one duration of each drug. It is very 
difficult to do a full dose ranging study with two drugs and 
combinations. A common recourse is to use a dose just at 
or below minimal efficacy for each individual drug, and 
then the combination, hoping for a dramatic improvement 
seen only with the combination. One must interpret these 
studies carefully. For example, one frequently quoted 
study of combined CSP and VOR for aspergillosis in guinea 
pigs showed reduced “positive lung cultures” of the combi-
nation over VOR alone and controls, but no increase in sur-
vival benefit8. This was considered a confirmation of the 
combination over single drug therapy (Fig. 1). However, 
if one looks carefully, there is no significant difference 
between the VOR alone and the combination. All animals 
survived. In other words, the dose of VOR was too high 
to have the desired “sub-threshold effect”. These studies 
are difficult to conduct, and readers often see conclusions 
in them that are beyond the strength of the data. Yet, 
despite inconclusive results, this and other such studies 
were used to launch the concept of combined antifungal 
therapy as superior to one drug.
Even in animal models the results in one laboratory do 
not always confirm those of the other. In one example, van 
de Sande and colleagues examined VOR and anidulafungin 
(ANID) alone and combined in a rat model of advanced IA9. 
In this study equivalent doses were used for the area under 
the curve... total drug exposure (AUC)… in humans for both 
drugs. Rats treated early in the course all survived, whereas 
rats treated late in the course had 56% survival at day 23. 
ANID given in late IA showed 18% survival, and combined 
with VOR added no benefit. In essence ANID was poorly 
active and gave no benefit in combination therapy.
Preclinical studies: Summary
In my view the in vitro data are useful to select a drug 
which has potential in the test tube and may then be 
taken to the much more costly animal studies. The animal 
studies incorporate pharmacokinetics, pharmacodynam-
ics, and give both efficacy and toxicity data in various 
regimens. However, they are very cost-limiting (as well as 
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Figure 1 Cumulative mortality of 12 guinea pigs per treatment group 
treated with caspofungin, voriconazole, caspofungin plus voriconazole, or 
amphotericin B. Guinea pigs were challenged on the second day. Controls 
(□) received no antifungal therapy. Treatment of the guinea pigs with 
amphotericin B at 1.25 mg/kg/day (△), caspofungin at 1 mg/kg/day (■) 
or 2.5 mg/kg/day (▲), voriconazole at 5 mg/kg/day (◊), caspofungin at 
1 mg/kg/day plus voriconazole at 5 mg/kg/day (*), or caspofungin at 2.5 
mg/kg/day plus voriconazole at 5 mg/kg/day (●) was initiated 24 h after 
challenge and was given daily for 5 day. Reused with permission. Original 
source: Antimicrob Agents Chemother. 2002;46:2564-8.8
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in ethics of using the masses of animals required) to study 
full ranges in combination studies. The few attempts (by 
ourselves and others) have severe limitations in explora-
tion of dose size and duration, and whether treatment 
is initiated early or late in the course of disease. What 
these data do give us are some cues as to how to approach 
human studies…which unfortunately. Preclinical studies do 
not give us any assurances regarding benefit, antagonism, 
or toxicity. For that, we must go directly to the patient, 
and my personal view is that for combination therapy all 
rises or falls on the clinical data alone.
Clinical evidence on combination  
antifungal therapy
It has been made abundantly clear for cryptococcosis, can-
didiasis, and aspergillosis that treatment very early in disease 
is much more effective than delayed therapy. Yet in clinical 
practice our innovative changes in drug regimens are usually 
made for patients in the last stages of a desperate course of 
“nothing is working”. We ask a great deal.
It is worth beginning with a brief review of the most 
clear-cut benefit of combination antifungal therapy. This is, 
of course, cryptococcal meningitis, and it is for this benefit 
that we strive with the treatment of other mycoses.
Cryptococcal meningitis
The first studies of combination antifungal therapy were 
conducted in non-HIV patients by Bennet et al., and pub-
lished in 19791. In that study combined flucytosine (5FC, 
150 mg/kg/day) and AMB were found more effective than 
AMB alone, and also less nephrotoxic than the latter. Four 
weeks of the combination was as effective as 6 weeks10. 
Flucytosine was not considered an effective single agent 
due to toxicity of the dose at 37.5 mg/kg/6 h, and to the 
emergence of resistance (to both C neoformans and to 
Candida as well)11. This combination regimen became the 
standard course of therapy for cryptococcal meningitis until 
the sharp rise in cryptococcal disease associated with HIV/
AIDS. The major problem then was that combination ther-
apy arrested meningitis, but with the continued immune 
suppression associated with HIV, the disease recurred after 
treatment was stopped. This and the cumulative toxicities 
of both AMB and flucytosine led to two major changes.
The first of these changes was the reduction in dose of 
5FC to 25 mg/kg/6 h12. This abrogated most of the myelo-
toxicity of flucytosine. A lower dose of Amphotericin B also 
reduced the nephrotoxicity and indirectly, the flucytosine 
toxicity, as flucytosine is excreted renally, and levels of its 
toxic metabolite, 5-fluoruracil, also rise in renal failure.
The second change was the development of fluconazole 
(FLU), a fungistatic drug for C. neoformans. While flucon-
azole had some benefit on its own, it was incorporated 
into studies of combined therapy by the MSG. The MSG 
found that an initial 2 weeks regimen of AMB and 5FC was 
marginally (P=.06) more effective in converting cerebro-
spinal fluid (CSF) cultures negative at 2 weeks than was 
AMB alone13 (Table 1). The actual difference favoring the 
addition of 5FC was only 9%, which does not convince me 
that 5FC really added much. At the end of 2 weeks, this 
induction regimen was followed by fluconazole at 400 
mg per day for 8 more weeks, then 200 mg per day for 10 
months (non-HIV) or until the CD4 count rose (above 100 
in HIV patients, with non-detectable HIV RNA for 3 months 
allows one to terminate therapy). Many patients clinically 
responded, and an important part of these studies was 
the adoption of a surrogate for clinical response…the CSF 
culture conversion after 2 weeks of induction therapy. 
Patients with persistent positive CSF cultures were often 
continued longer on the induction regimen. Because 5FC 
is not available in many parts of the world, and because 
the results only marginally favored it, many clinicians use 
combined induction therapy, while others use a single drug 
with AMB (or liposomal AMB) alone. The brevity of AMB, 
and the 25 mg/kg/6 h 5FC dose, makes for a regimen with 
less toxicity and a lower need for monitoring hematology 
or renal function.
A prospective randomized open label trial in Thailand 
and the US compared AMB (0.7 mg/kg for 14 days, fol-
lowed by fluconazole 400 mg per day to day 56) versus 
AMB plus FLU at 400 mg per day for 56 days or AMB plus 
FLU 800 mg per day for 56 days14. The results were dif-
ficult to interpret, in part due to comparing several time 
points for response with patients in 2 different countries, 
with some on or off antiretroviral treatment, and using 
a overall clinical response which included both clinical 
improvement and negative CSF cultures at 2 weeks. At day 
14, 41% of those on standard AMB followed by FLU, 27% of 
those on the FLU 400 mg combination, and 54% of those on 
the 800 mg FLU combination had successful responses. The 
authors claimed a “trend” to benefit of the combinations. 
In my view, this study is flawed by not using enough FLU 
(400 and 800 mg doses are fungistatic while 1200 mg is 
fungicidal) and that the major difference was FLU in just 
the first 2 weeks of therapy… i.e. not a very bold study 
design and containing patients grouped in too many cells.
Use of the CSF culture conversion after 2 weeks of 
therapy was eventually considered an insensitive surrogate 
for microbiological response. Bicanic et al. correlated out-
come with initial fungal burden and with early fungicidal 
activity (EFA), measured as daily log reduction counts in 
the CSF, determined through multiple lumbar punctures 
in the first 2 weeks of therapy15. High fungal burden was 
associated with poor outcome, and high EFA was associ-
ated with improved outcome.
Several, more recent, studies adopted the EFA as the sur-
rogate for microbiological response, replacing the 2 week 
culture sterilization. This was initially used in animal models, 
and when advanced to clinical application, was found to be 
very sensitive in a study by Brouwar et al.16. In their study, 
groups of 15 patients were randomized to AMB+5FC, AMB 
alone, AMB+FLU, or all 3 drugs. The investigators found that 
a high fungal burden (i.e. late stage disease) correlated with 
poor outcome. Just as important, the investigators changed 
their surrogate for response to the early reduction in cryp-
tococcal counts in cerebrospinal fluid (ERC, same as EFA). 
This necessitated more lumbar punctures, but gave a more 
sensitive index of response than the 2 week culture conver-
sion. In most of the more recent studies this criterion has 
been used. The EFA, as per Figure 2, showed superiority of 
AMB and 5FC (EFA = -.54+0.19 log CFU/ml CSF/day) over the 
other regimens.
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However, results were not always reproducible. A fol-
low-up study by Loyse et al., compared regimens with 
combinations of AMB and other drugs17, Their responses 
showed that AMB (0.7-1 mg/kg/day) + 5FC had an EFA of 
-0.41+0.22 log CFU/ml CSF/day, AMB + FLU 800 mg per day 
(EFA - 0.38 + 0.18 log CFU/ml CSF/day), AMB + FLU 600 
twice daily (EFA -0.41 + 0.35 log CFU/mL CSF/day), and 
AMB + VOR 300 mg twice daily (EFA-0.44 + 0.20 log CFU/
mL CSF/day), all had similar EFA. These results could not 
select out any superior regimen, and had the disadvantage 
that all regimens include AMB. Further, none were as good 
as AMB+5FC results by Brouwer et al.16. There were only 
13-23 patients per group.
Immune augmentation has been examined only once. 
The Mycoses Study Group supported a Phase II comparison 
of a traditional regimen of AMB + 5FC for 2 weeks, followed 
by FLU 400 mg per day for 8 weeks, with this regimen plus 
interferon gamma administered 3 times per week for the 
full 10 weeks18. At 2 weeks the negative CSF cultures were 
13%, 36%, and 32% of placebo, IFN-γ 100 µg, and 200 µg 
recipients, respectively. In this study of 70 patients, there 
was a “trend” (P=.22, for the 100mcg dose of IFNG versus 
0.078 for both 100 and 200 mcg doses combined). I would 
also consider this study inconclusive rather than clear evi-
dence of superior efficacy for the IFNG / antifungal drug 
combination.
A more exciting era in chemotherapy came with com-
binations of 5FC and FLU, in an effort to eliminate AMB 
altogether. A randomized study of FLU versus FLU + 5FC in 
Uganda showed no significant differences in 6 month survival, 
but the FLU dose was only 200 mg per day19. An open study 
by Larsen et al. suggested that an all oral regimen of flucon-
azole with 5FC was effective in cryptococcal meningitis20. 
This was found effective in open studies, with higher doses 
of FLU (1200 mg) giving better results. Indeed, high doses of 
FLU given alone were found to reduce C. neoformans counts 
in CSF more effectively than lower doses… so the “usual” 
dose may not be optimal21,22. FLU at 1200-2000 mg/day was 
recommended in the 2010 IDSA Guidelines as an alternative 
therapy, based on results at high doses12.
Figure 2 Amphotericin B and flucytosine (5FC had a higher early fungicidal activity compared with Amphotericin B alone (p=0.006), 
Amphotericin B + fluconazole (p=0.02) or triple drugs therapy (p=0.02). Reused with permission. Original source: Lancet. 2004;363:1764-7.16
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These studies describe a progression from early therapy 
with combined AMB and 5FC to more recent studies with 
combined AMB and FLU and FLU and 5FC. These regimens 
are being further examined in countries where cryptococ-
cosis is a greater clinical issue than in the United States 
(e.g. South Africa, Thailand).
One randomized prospective trial was conducted in 
Malawi with FLU1200 mg per day alone or combined with 
5FC at 100 mg/kg/day on HIV positive, non HAART treated 
patients with their first episode of cryptococcal meningi-
tis23. EFA was the primary end point, and was determined 
as the slope of reduction of cryptococcal counts from lum-
bar punctures done on day 1,3,7, and 14. EFA of the combi-
nation was -.28+0.17 log CFU per day for the combination 
versus -0.11±0.09 log CFU per day for FLU alone (P<.001) 
(Fig. 3). This was remarkable in that only 41 patients were 
analyzed. The conclusion of this study was that an all oral 
regimens with high dose fluconazole and oral flucytosine 
can be constructed in Africa, where it is very difficult to 
administer AMB. This small study also showed a reduction in 
mortality at 2 weeks for the combination (10% of 21) versus 
fluconazole alone (37% of 19) [P=.05].
In summary, there is strong support for combined 5FC 
and AMB for induction therapy of 2 weeks, followed by 
FLU for long term therapy, which continues until the 
CD4 counts rise in HIV patients, or 10 weeks in non-HIV 
patients. However, the more important discoveries, also 
based on multiple studies, have been the increased effi-
cacy of high dose FLU, and the ability to use an all oral 
regimens (FLU and 5FC) for induction therapy. These 
major advances depended in part on the adoption of EFA 
as a surrogate for response, a practice unfortunately not 
done universally. They make a strong case for distribution 
of 5FC worldwide, and not to penalize patients in coun-
tries where this component of an all oral regimen is not 
available. Cryptococcus gattii is managed in just the same 
way as C. neoformans for meningitis.
For the rare patient unable to tolerate fluconazole, 
both VOR and posaconazole have some efficacy in cryp-
tococcal meningitis. But they have not been extensively 
studied in primary therapy or with combinations.
Finally, the immune reconstitution syndrome is mani-
fested by headache and increased inflammation in the 
CSF. It is not associated with antifungal therapy failure, 
which should not be changed. If needed, brief courses of 
corticosteroids may reduce the manifestations of immune 
reconstitution syndrome24.
Candidemia
Initial studies of AMB combined with 5FC were scattered 
cases. The use of 5FC in neutropenic patients was a detri-
ment, and no clear benefits were shown. The appearance of 
FLU, a relatively non-toxic but fungistatic azole, led to studies 
of combined AMB and FLU in candidemia. While FLU had activ-
ity of its own in candidemia, there was not enough push to 
set up a 3 arm study. Hence FLU was compared with FLU and 
AMB. The clinical data related to combination therapy essen-
tially hang on the prospective randomized study by Rex and 
Figure 3 Early fungicidal activity in patients treated with fluconazole (1200 mg per day) versus fluconazole and flucytosine (100 mg/kg/day).  
A: fluconazole 1200 mg per day. B: fluconazole and 5FC 100 mg/kg/day. Reused with permission. Original source: Antimicrob Agents Chemother. 
Clin Infec Dis. 2010;50:338-44.23
Table 1 Outcomes in prospective randomized trial of 
fluconazole versus fluconazole and amphotericin B in 
systemic candidiasis. Reused with permission. Original 
source: Clin Infect Dis. 2003;36:1221-8.25
FLU 800 mg/day FLU + AMB P
Number 107 112 -
Success 57% 69% 0.043
Persist. Pos. Blood Culture 17% 6% 0.02
Death 90 days 39% 40% NS
8
7
6
5
4
3
2
1
0
8
7
6
5
4
3
2
1
0
Lo
g 
CF
U/
m
l C
SF
2 4 6 8 10 12 14 16
Day
2 4 6 8 10 12 14 16
Day
A B
Combination Antifungal Therapy: Is it for everyone and every mycosis? 17
the MSG25. In this large prospective randomized trial, patients 
were randomized to 800 mg per day FLU versus FLU and AMB 
0.7 mg/kg/day. Success was defined as resolution of symptoms 
and negative blood cultures (Table 1). The combination was 
favorable, P=.048, and candidemia persisted longer with FLU 
therapy. However, this is presented a little more clearly than 
it really is. The pre-defined criteria for success included time 
to failure, where the P was 0,08 (Fig. 4). Ninety day mortal-
ity also showed no differences. If overall success rate is used, 
(a secondary analysis) the P required for significance,was 
.045, and 0.043 was achieved. The clearest benefit for the 
combination was found in another secondary analysis, when 
the authors broke down their patients according to APACHE II 
(fig. 5). Herein, the combination performed better than single 
drug than was noted for patients with midrange APACHE II 
scores (approximately between 10 and 22). In other words, 
when the APACHE II score was low, patient immune defenses 
were sufficient to cause low mortality, with a relatively minor 
contribution of either single or combined antifungal therapy. 
In patients with APACHE II scores in the 20’s, mortality was 
high no matter what regimen was used. Host immune defenses 
clearly played a critical role, and when these were abrogated 
severely, antifungal regimens were less critical. This shows, 
ever so clearly, the effect of the severity of underlying disease 
on treatment outcome, and the limitations of antifungal ther-
apy. As most of us do not use APACHE II scoring to determine 
our therapy, using these data in clinical decision making is not 
easily done.
The 2009 IDSA Guidelines had only this curious and some-
what dismissive comment about the Rex study: “In large clini-
cal trials, fluconazole demonstrated efficacy comparable to 
that of AmB-d for the treatment of candidemia…”6 Indeed, the 
IDSA Guidelines do not recommend combined AMB and FLU for 
candidemia. The final icing on this cake was provided by the 
echinocandins, which had equal or higher efficacy than other 
antifungals. As one example, in a randomized comparison ANID 
(200 mg day 1 then 100 mg per day) was more effective at end 
of therapy than FLU alone (800 mg day 1 then 400 mg/day), 
(P=.02)26. At present, echinocandins are recommended as pri-
mary therapy in patients severely ill with candidemia and FLU 
or AMB are recommended as alternatives for some patients6.
In summary, the Rex study is the definitive study on anti-
fungal drug combinations in candidemia, at least for azoles 
and AMB. By days to response there was no significant differ-
ence. By number of responders there was a barely significant 
difference. By clearance of candidemia there was a very 
significant difference. By mortality there was no significant 
difference. AMB is toxic. One cannot conclude that there is 
much value for this combination.
A second series of studies involved immune defense as 
one of the arms of antifungal therapy. In this study, with 
supporting murine data, patients were randomized to treat-
ment with AMB, with or without the addition of a monoclo-
nal heat shock protein Candida antibody27. Results for this 
randomized placebo controlled trial were very impressive, 
strongly favoring the combination. Of 119 patients analyzed 
by modified intent-to-treat, complete response (improve-
ment and negative blood cultures) was seen in 48% of those 
who received (liposomal AMB) LAMB versus 84% of those who 
received LAMB plus a Candida heat shock protein antibody 
(P=.001). More rapid sterilization of blood cultures was also 
seen. However, there have been some challenges to the 
Figure 4 Time to failure of patients with candidemia treated with 
fluconazole or fluconazole and amphotericin B. P=0.0925.
Figure 5 APACHE II distribution and success rate, by APACHE II score. A. 
Distribution of APACHE II scores for the fluconazole plus amphotericin 
B deoxycholate (solid line) and fluconazole plus placebo (stippled line) 
groups. B. Outcome by group (solid line, fluconazole plus amphotericin 
B deoxycholate; stippled line, fluconazole plus placebo) for subjects 
with the same APACHE II score ± 5 points (e.g., the leftmost point of 
each line is the success rate for subjects having an APACHE II of 6 ± 5, 
or 1-11). The cell width of ± 5 for this rolling stratified analysis was 
chosen because it placed ≥ 10 subjects into each cell. Qualitatively 
similar results were obtained for cell widths ± 3 and ± 4. Reused with 
permission. Original source: Clin Infect Dis. 2003;36:1221-8.25
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reported efficacy of Mycograb (also named Efungumab), and 
a cytokine release syndrome has been associated with unsta-
ble blood pressure and cardiac output. Mycograb has not 
been approved in Europe, pending further controlled studies, 
and is an orphan drug per the US Food and Drug Administra-
tion28. This is particularly unfortunate, as a number of other 
studies with antibodies and cytokines against Cryptococcus 
neoformans and against inflammatory mediators in other dis-
eases, such as coccidioidomycosis, have been tried only in a 
few cases, with no conclusive results.
Invasive aspergillosis
This disease is the current leading problem of IFI. Inva-
sive aspergillosis is presently associated with a variety of 
predisposing factors, including high dose steroid usage, 
hematological malignancy neutropenia, stem cell trans-
plantation, especially with graft versus host disease, 
solid organ transplantation. Pathogenesis is almost always 
by infection following inhalation of conidia, germina-
tion in alveoli and small airways, penetration of hyphae 
into blood vessels, and ultimately widespread hemato-
logical dissemination. IA is associated with mats of hyphae 
obstructing blood vessels, initially in the lungs, but also in 
other target organs. Distal tissue infarction is a hallmark 
of this disease. Initial manifestations of IA are early onset 
of pneumonia following an immunologic suppression….and 
efforts were made to prevent this disease by using HEPA 
filtration in the hospital rooms of vulnerable patients. 
However, in more recent years IA has appeared in both 
early and later phases of leukemia, commonly associated 
with graft versus host disease, treatment with steroids, 
and other immune suppressive medications. Furthermore, 
the rise of heart/lung transplantation has generated a 
whole new series of manifestations of IA, including local 
necrotizing tracheobronchitis, focal pulmonary invasion, 
and widespread pneumonia. All of these have given IA a 
much broader range of disease and virulence than in ear-
lier years. Treatment initially was acute, associated with 
high mortality often exceeding 80% for AMB, and then was 
dramatically improved with the introduction of VOR. More 
recently, a switch to LAMB has substantially reduced the 
toxicity of AMB. VOR associated mortality was still over 
29% at 12 weeks, and interest soon turned to the possibil-
ity of combination therapy29.
In 2004 Marr et al. published a very provocative paper, 
a study of salvage VOR response to IA associated with 
HSCT, compared with combined VOR and CSP30. There 
were 47 patients treated between 1997 and 2001. Forty 
one of these patients were HSCT recipients. Standard 
practice at that time was to use AMB ≥ 1 mg/kg for pri-
mary therapy and VOR for rescue therapy. In February 
2001 salvage therapy was altered to include VOR plus CSP 
70 mg day 1 then 50 mg/day. Survival at 3 months after 
diagnosis was higher for the combination (P=.08) and 
when measured after initiation of salvage therapy it had 
a P=.045, favoring the combination (Fig. 6). With univari-
ate Cox regression, the combination gave a hazard ratio of 
0.42 and P=.048, thus favoring the combination. However, 
non-myeloablative therapy had a hazard ratio of 0.30 with 
a P=.052. Is there much difference between P=.048 and 
P=.052? With multivariate Cox regression analysis, the 
combination reduced the risk of death associated with VOR 
alone, HR 0.27, P=.008, with receipt of transplant giving a 
P=.06, and non-myeloablative therapy dropping out.
A main strength of this study included using all cause 
mortality (no fudging as to who died of IA). The responses 
to combined therapy were clearly better than to VOR 
alone, or were they? The initial appearance of a positive 
effect needs to be examined more closely. First, this was 
not a randomized trial, but a prospective study of a com-
bination compared with a retrospective analysis of VOR 
Figure 6A Kaplan Meier survival plot of patients receiving VOR  
or VOR and CSP for salvage therapy of IA. P is 0.048 from the 
likelihood ratio test using Cox regression. Note small number of 
patients at 90 days. . Reused with permission. Original source: Clin 
Infect Dis.2004;39:797-802.30
Figure 6B Probability of death rom invasive aspergillosis. Patients  
with GVHD and IA were considered to have died of IA while those with 
relapsed malignancy were considered to have died of the malignancy. 
P=0.024 favoring the combination. Reused with permission. Original 
source: Clin Infect Dis.2004;39:797-802.30
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alone. This was, in essence a historic comparison, and 
the numbers were very small, 31 for VOR, and only 16 for 
combined therapy. Despite the similarity of groups in the 
demographics presented, such studies are prone to unap-
preciated differences in the demographics of treatment 
groups. The small numbers, and some differences between 
the treatment groups (HSCT as one example) exaggerated 
this weakness. Furthermore, when the comparisons of out-
come were extended beyond the initial published observa-
tions, the overall mortality of both groups came together. 
The very small numbers at the end of observation (10 per 
group) seriously limit comparisons.
Another unappreciated problem is the generally limited 
database for echinocandins in IA. Why did the authors choose 
CSP? An open study of rescue therapy with CSP in very well 
defined patients showed efficacy in a very small number of 
CSP recipients31. Even in this carefully conducted study of 83 
patients, there were two distinct groups. One was 71 patients 
failing conventional therapy, and the other was 12 patients 
treated with CSP for drug toxicity of the primary therapy 
(AMB). This latter group had a 75% response while that for 
failing patients was 39%... only half as good. The combined 
response to CSP was 45%. Combinations of CSP with VOR and 
other agents have been reported to be in the same range, 
55%32. Other studies had similar results, using a variety of 
combinations. Overall, echinocandin efficacy in IA is based 
on a variable data base, often retrospectively collected, and 
not readily comparable with other studies. And the results 
are not especially encouraging in patients with late stage dis-
ease. The newer echinocandins, micafungin and ANID, have 
a much more poorly constructed data base than CSP. Most of 
the data with micafungin are based on combination with AMB 
or VOR, so it is impossible to determine MF result alone33. 
Response rates of 194 patients given micafungin in combina-
tion with other drugs was collectively only 34%, so this is not 
much to get excited about. So while we have very good data 
on VOR and AMB response in IA, it is much more sketchy for 
the echinocandins in IA. Nevertheless, based on the Marr 
study, there was considerable popular support for using echi-
nocandins with VOR, at least in rescue therapy for IA. Merck 
did acquire data on toxicity of combined CSP and VOR (no 
added toxicity), but  did not support a primary randomized 
trial of single vs combined therapy.
Yet another study, a “prospective observational study”, 
was reported by Singh et al., on patients with liver trans-
plantation and primary treatment of IA34. This really was 
a historical study in which 47 patients treated in 1999 to 
2002 received LAMB, versus 40 patients from 2001-2005, 
who were given combined VOR and CSP (n=40). Ninety 
day survival was 67% for the combination recipients ver-
sus 51% for the LAMB recipients (P=.117). However, in 
secondary analyses the authors found a significant ben-
efit in those with renal failure and those with Aspergillus 
fumigatus. The problems with this study include a) its his-
torical nature b) small size and, c) the secondary analyses, 
done with small groups of patients, poorly powered, and 
reaching for something, anything, which was “good”. The 
authors concluded that combination therapy “might be 
considered” preferable for special groups. That is a very 
qualified endorsement.
These types of studies in themselves are extremely rarely 
the foundations for major changes in medical practice. The 
best that they can properly do is to raise the question of 
whether combination therapy is superior to a single agent. 
The question should be answered by a sufficiently powered 
randomized prospective comparison. However, as time 
passed, many physicians did not wait, and began to use 
combinations in primary or rescue therapy of IA.
After a considerable delay, a multicenter prospective 
study was developed by the MSG for HSCT transplant recipi-
ents with probable or documented IA. The sponsors and the 
investigators are to be complimented for diligently pursu-
ing this study. The regimens were VOR (6 mg/kg/12 h IV 
decreasing to 4 mg/kg/12 h) versus ANID (200 mg V day 1 
decreasing to 100 mg/day thereafter) and VOR randomized 
1:1. After 1 week the VOR could be switched to oral drug 
at 300 mg/day. Combination therapy was continued for 
2-4 weeks. The endpoint was death at 6 weeks in patients 
with confirmed or probable IA diagnosed at day 7. Second-
ary endpoints were global response at 6 weeks, all cause 
mortality at 12 weeks, and safety/tolerability. The study 
recently closed, and preliminary data were presented 
at the 2012 ECCMID meeting35. Of 454 patients entered, 
277 were adjudicated to have documented or probable 
IA). Six week mortality in the 135 patients who received 
combination therapy was 19%, versus 28% of those who 
received VOR alone (P=0.09), which just makes the cut for 
a “trend,” favoring the combination. In other words the 
responses were close to good enough, but not quite good 
enough for a “conclusive” answer. If we want to use the 
combined regimen, this may be “good enough” for some. 
The authors reinforced this by presenting the data for 
patients in whom the microbiological basis for probable IA 
was only the galactomannan assay, the results significantly 
favored the combination therapy group, with a P just a bit 
below .05. Details are also given in Table 2. The authors 
Table 2 Outcome of invasive aspergillosis in patients randomized to voriconazole or voriconazole and anidulafungin35
Parameter VOR n (%) VOR+ANID n (%) P 95% CI
Death 6 Wk. 39 (27.5) 26 (19.3) 0.09 -19,1.5
Death 12 Wk. 55 (39) 39 (29) 0.07 -21,1.09
Death Attributed to IA 33 (23) 23 (17) 0.2 -15.9,3.42
Overall Success 61 (43) 43 (32) 0.08 -21.6,1.15
Death 6 Wk. Prob. IA 39 (14) 24 (9) 0.05 -20,0.3
Death 6 Wk. GM based Dx 30 (27.3) 17 (15.7) 0.04 -22,-0.4
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appropriately concluded that their results showed a trend 
to improved survival, but then threw in the “probable IA 
diagnosed with GM only” as an analysis. Is this playing by 
the rules of analysis according to success criteria defined 
before the study commenced, or is this post hoc analysis? 
This is a preliminary presentation, which I did not attend, 
and I cannot easily judge.
My point is that we are not neutral, but want to use what 
we hope will be more effective. A suggestion (P=.09) is bet-
ter than nothing at all… or is it? If we cannot quite prove a 
benefit, does “almost proof” become good enough? What if 
the P is .06, or .08? Fortunately, there were no additional 
toxicities, which is good, but this is of much less importance 
compared with efficacy. But is the trend to benefit good 
enough to adopt combination therapy routinely? I think 
not. Let us return to cryptococcosis, where multiple studies 
using different regimens have clearly confirmed the value of 
combined therapy. It should not be that hard to show a real 
benefit in IA if there is a real benefit… at least with these 
regimens given for primary therapy, i.e. early disease. Recall 
that this is not salvage therapy, with patients treated late in 
the course of disease. This should be more like the VOR vs 
AMB study, or the patients given CSP for “toxicity” salvage 
(70% response), not clinical salvage (35% response).
With a large study such as this, with patients carefully 
selected for high probability of IA, if the initial response 
was not quite clear-cut, the authors had to work to show 
a benefit, which was barely significant when other pre-
defined criteria for success were not achieved? This type 
of secondary analysis, is often used, and may have sig-
nificant contributions. But is it objective, or turning over 
the ground looking for something, anything? This is surely 
where Dr Kibbler and I disagree.
Zygomycosis
This has been a fertile area of preclinical investigation. 
Because zygomycetes have an avid iron capturing system, 
and because one predisposing clinical factor is iron over-
load disease, investigations were conducted in mice using 
combined AMB and an iron chelating compound. The 
combination appeared superior to AMB alone, decreasing 
tissue fungal burden presumably by starving the fungus of 
iron36. Unfortunately, zygomycosis is so uncommon that 
randomized prospective trials are almost impossible to 
contemplate in humans. A few cases gave a mixed report. 
In one of them a patient was treated with AMB and CSP 
for zygomycotic liver abscess, and then posaconazole was 
added. There appeared to be some initial stabilization. 
Then deferasirox was added and the disease became 
much more aggressive locally and metastasized, with a 
lethal outcome37. An initial case series suggested a worse 
outcome with the combinations, and this was dropped. 
Another area of interest is echinocandins. These have 
no demonstrable activity alone in zygomycosis in vitro, 
but in animal studies they added AMB38. Again, positive 
animal studies should initiate clinical investigation, but 
these on their own rarely indicate definitive change in 
therapy. A few case studies have suggested that com-
bined therapy might be superior to AMB alone39. The larg-
est of these is a series of 41 cases collected from 1994 to 
200640. Of these, 83% were diabetics of whom 41% were 
given corticosteroids. Only 12% were neutropenic. Suc-
cess, (being alive and not on hospice care 30 days after 
hospital discharge) was achieved by 54%. Five patients 
received CSP and ABLC, while 2 received CSP and LAMB 
as initial therapy. Four patients (one combination and 3 
monotherapy with polyene) were lost to follow-up within 
30 days of discharge, and were considered non-evaluable. 
Of the evaluable patients, 100% of 6 combination therapy 
recipients (including 4 with CNS disease) versus 45% of 
31 patients given polyene alone (and 25% of 16 with CNS 
disease) were considered successes (P=.01). The authors 
noted that from 1992-1997 AMB was the primary mode 
of therapy (60% of 5 cases successes); from 1997-2002 
lipid forms of AMB were used as monotherapy (44% of 
18 patients successes), and from 2004-1006 combination 
therapy was used (57% of 14 patients successes). There 
appeared to be no differences in outcome between these 
periods by multivariate analysis, and they claimed that 
only combination therapy remained significant. However, 
there are 2 major problems with this study. The first is 
that it is historic… an uncontrolled case series. There 
was no clear indication as to why some got the combina-
tions versus monotherapy. Although the surgeons were 
unchanged, there was no straightforward way to evalu-
ate the impact of surgery on these patients. Clearly the 
time of intervention is critical. The interval from onset 
of symptoms to initiation of therapy was often not given 
(how many were early versus late in their course). And 
how much variation was there in underlying immune 
deficiency among patients receiving monotherapy ver-
sus combination therapy? Any of these factors are mul-
tiplied by considering that there were only 6 patients 
receiving combination therapy (during a narrow time 
frame from between 2005 and 2007) compared with 31 
patients treated over a much longer time frame. Six is 
a very small number. Indeed, if one examines only the 
14 patients treated between 2004 and 2006, only 3 of 
the 8 patients receiving monotherapy responded (37%). 
This appears to be lower than the patients in earlier 
years given monotherapy with polyene. This could be 
consistent with “cherry picking” the patients most likely 
to respond to any treatment for primary combination 
therapy. Calls for randomized studies by these authors 
and those of an accompanying editorial40-42 are not likely 
to generate much response, with this uncommon group 
of mycoses. These cases are hard to evaluate, as medi-
cal therapy is often combined with surgical debridement 
to remove infarcted tissue, and early debridement also 
improves outcome. Issues of funding remain paramount 
for these uncommon mycoses. The area of zygomycosis 
will probably remain unresolved as regards combination 
therapy.
Summary
The above review suggests that one can clearly show effi-
cacy of antifungal combinations in cryptococcal meningitis, 
but this has been very difficult to show for other major 
mycoses. This leads one to consider what other measures 
are important in determining outcome. For the angio-
invasive molds, surgical debridement is a major component 
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of both early and late treatment. Commonly used in zygo-
mycosis, it may also be appropriate in persons with IA and 
other invasive molds. The reasons are both to prevent hem-
orrhage of infarcted tissues and to remove tissues where 
the antimicrobials do not penetrate. The best option is to 
initiate treatment very early, when there is little infarcted 
tissue, to allow antifungals penetrate the areas around the 
focus of infection. Initial studies by Garey et al. showed 
markedly improved outcome for candidemia (not strongly 
associated with infarction) if treatment was initiated within 
a day of the blood culture43. Treatment of patients with the 
halo sign, indicative of early invasive aspergillosis (strongly 
associated with infarction), was associated with better out-
come than other cavities or solid lesions representing later 
disease44. Similar results were presented for zygomycosis. 
Delaying treatment for more than 6 days doubled mortal-
ity, from 48 to 84% in 70 consecutive patients (P=.004)45. It 
is my belief that very early initiation of therapy has more 
benefit than chasing will o’ the wisp combinations, if for no 
other reason than antifungal drugs are likely to penetrate 
already necrotic tissue. This is not a call for abandonment 
of exploration of combination antifungal therapy. It is rec-
ognition that the regimens we have thus far, except for 
cryptococcosis, have not been solidly effective, and that 
attention may be better focused on improving standards for 
very early diagnosis, and launching therapy either pre-emp-
tively or even empirically limited to very high risk groups. 
This might be combined with early withdrawal if IFI is not 
quickly confirmed. This takes us into an area beyond the 
scope of this paper.
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